SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178913-23-000670
Filing Date
2023-02-21
Accepted
2023-02-21 06:10:48
Documents
73
Period of Report
2022-12-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2329164.htm   iXBRL 8-K 146711
2 EXHIBIT 99.1 exhibit_99-1.htm   iXBRL EX-99.1 876112
8 GRAPHIC cmmb_img01.jpg GRAPHIC 2815
  Complete submission text file 0001178913-23-000670.txt   5175204

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cmmb-20221231.xsd EX-101.SCH 56413
4 XBRL CALCULATION FILE cmmb-20221231_cal.xml EX-101.CAL 46539
5 XBRL DEFINITION FILE cmmb-20221231_def.xml EX-101.DEF 128511
6 XBRL LABEL FILE cmmb-20221231_lab.xml EX-101.LAB 489385
7 XBRL PRESENTATION FILE cmmb-20221231_pre.xml EX-101.PRE 263879
67 EXTRACTED XBRL INSTANCE DOCUMENT zk2329164_htm.xml XML 757494
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 23645128
SIC: 2834 Pharmaceutical Preparations